



Case 3:04/1

TECH CENTER 1600/2900

APR 6 2003

RECEIVED

71617

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Joel Krasnow

GROUP ART UNIT:

SERIAL NO.: 10/067,128

EXAMINER:

FILED: 4 FEBRUARY 2002

DATE: March 24, 2003

TITLE: METHOD OF USING A CYCLOOXYGENASE-2 INHIBITOR & SEX STEROIDS AS A COMBINATIONS THERAPY FOR THE TREATMENT & PREVENTION OF DYSMENORRHEA

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97-1.98

Commissioner of Patents and Trademarks
Washington, D.C. 20231
Sir:

This Supplemental Information Disclosure Statement is filed pursuant to 37 CFR 1.97-1.98 and MPEP §609. The present Information Disclosure Statement, supplements the Information Disclosure Statement being filed herewith simultaneously. Any fee required by 37 CFR 1.97-1.98 should be charged to Deposit Account No. 19-1025.

This newly cited document is as pertinent as the documents previously cited in this prosecution.

Respectfully submitted,

James M. Warner

James M. Warner
Attorney for Applicants
Registration No. 45,199
(314) 274-3642 (St. Louis)

Pharmacia Corporation
P.O. Box 1027
Chesterfield, MO 63006

RECEIVED

APR 04 2003

TECH CENTER 1600/2900
Sheet 1 of 1

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.: 3414/1	APPLICATION NO.: 10/067,128
	INVENTOR: Joel Krasnow	
	Filed: 02/04/2002	Group:

FOREIGN PATENT DOCUMENTS

Examiner Initial							Translation	
		Document Number	Date	Country	Class	Subclass	Yes	No
	B1	WO 97/31631	09/04/1997	PCT				

EXAMINER	DATE CONSIDERED	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

(Form PTO-1449)